Therapeutic resistance in depression from the genetics and pharmacogenetics point of view

Abstract

Current trends in the concept of therapeutically resistant depression (TRD) tend to narrow its very heterogeneous group of patients. One of the most rapidly developing areas in the biological paradigm of TRD is genetic research aimed at finding biomarkers for predicting the therapeutic response. Obviously, the genetic risks of TR are not limited to combinations of genome genetic variants, but it also has phenotypic manifestations at all levels of phenotype formation. According to the fundamental possibility of achieving remission states, therapeutic resistance can be divided into relative and absolute. At present, it can be said that patients with relative and absolute resistance represent two biologically heterogeneous groups, the isolation of which requires the development of special laboratory approaches that will contribute to the development of a personalized approach to therapy.